ERBB2 and breast carcinoma: HER2 is a rational target for ADCs in breast cancer as about 15% of breast cancers show HER2 protein overexpression and/or HER2 gene amplification [6], and a further 50% show a low-level expression of HER2 without HER2 amplification [9,10].